Semaxanib

CD309, CD309 antigen, EC 2.7.10.1, FLK-1, FLK1, mouse, homolog of, FLT, FLT-4, FLT41, FRT, Fetal liver kinase 1, Flt-1, Fms related tyrosine kinase 1, Fms related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), Fms related tyrosine kinase 1 vascular endothelial growth factor/vascular permeability factor receptor, Fms related tyrosine kinase 4, Fms-like tyrosine kinase 1, Fms-like tyrosine kinase 4, KRD1, Kdr, Kinase insert domain receptor, Kinase insert domain receptor (a type III receptor tyrosine kinase), LMPH1A, Ly73, PCL, Protein-tyrosine kinase receptor flk-1, Soluble VEGF receptor 1 14, Soluble VEGFR1 variant 2, Soluble VEGFR1 variant 21, Soluble VEGFR3 variant 1, Soluble VEGFR3 variant 2, Soluble VEGFR3 variant 3, Tyrosine kinase growth factor receptor, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Tyrosine-protein kinase receptor FLT4, VEGFR, VEGFR-1, VEGFR-2, VEGFR-3, VGFR1_HUMAN, VGFR2_HUMAN, VGFR3_HUMAN, Vascular endothelial growth factor receptor 1, Vascular endothelial growth factor receptor 2, Vascular endothelial growth factor receptor 3, Vascular endothelial growth factor receptor 3 precursor, Vascular endothelial growth factor vascular permeability factor receptor, Vascular permeability factor receptor, Vascular permeability factor receptor 1, soluble VEGFR2

Biochemicals